UNICYCIVE THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -0.45% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-30
- UNICYCIVE THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -0.45%, a 169.23% decline from fiscal 2024.
- UNICYCIVE THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was 0.65%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2025-12-31 | -0.45% 10-K · filed 2026-03-30 |
| 2024-12-31 | 0.65% 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |